A Phase 1/2 interventional study of Fecal Microbiota Transplantation (FMT) Capsules and Placebo capsules in Heart Failure With Preserved Ejection Fraction (HFPEF) and Chronic Heart Failure, sponsored by The First Affiliated Hospital of Air Force Medicial University. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by The First Affiliated Hospital of Air Force Medicial University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.
Among the 377 studies in Heart Failure with a site in China, this one is the 190th largest by planned enrollment of the 247 interventional ones that give a count, is one of 43 that started in 2026, is one of 14 in phase 1/2, reaches primary completion later than 103 of the 181 other live ones, and was the 357th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
AstraZeneca · Sites in China, United States, Argentina and 29 more countries
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
Tasly Pharmaceutical Group Co., Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 44 · Phase 3 49 · Phase 4 30
First in 1983; this study’s year is marked. 43 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 130 across the 247 interventional studies, 554 across the 130 observational. Of the 117 that completed or were terminated, 33 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 377 have an industry lead sponsor. The 10 most frequent:
The First Affiliated Hospital of Air Force Medicial University is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
The First Affiliated Hospital of Air Force Medicial University has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
47 of the studies in Heart Failure with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07496372Phase 3HELP Therapeutics Co., Ltd.A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | 2027-06-30 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06927440Shanghai Jiao Tong University School of MedicineNational Multicenter Registry for Pediatric End-Stage Heart Failure in China | 2026-11-30 |
Add all 47 to your calendar (.ics) → With an account.
Among the 377 studies in Heart Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) in elderly patients with heart failure with preserved ejection fraction (HFpEF).
HFpEF is a common type of heart failure in older adults, often associated with poor quality of life and frequent hospitalizations. Recent research suggests that changes in gut bacteria may contribute to the progression of HFpEF. FMT aims to restore a healthy gut microbiome, which may improve heart function and reduce symptoms.
Participants will be randomly assigned to receive either FMT or a placebo treatment. The primary goal is to compare changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score between the two groups at 20 weeks. Secondary goals include assessing improvements in exercise capacity (6-minute walk test), NYHA functional class, and safety outcomes.
The study will enroll 50 elderly patients (aged ≥60 years) with confirmed HFpEF. All participants will receive standard medical care for HFpEF throughout the study. This trial is sponsored by The First Affiliated Hospital of Air Force Medical University and conducted in accordance with ethical standards.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
2.Meeting the diagnostic criteria for HFpEF:
Meet at least one of the following conditions:
Exclusion Criteria:
2.Patients with any to Fecal Microbiota Transplantation (FMT):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Fecal Microbiota Transplantation (FMT) Capsules
Biological: Placebo capsules
Bowel preparation with polyethylene glycol (PEG) before treatment, followed by oral administration of fecal microbiota transplantation (FMT) capsules. Patients will receive standard HFpEF medical care throughout the study.
Bowel preparation with polyethylene glycol (PEG) before treatment, followed by oral administration of identical-appearing placebo capsules. Patients will receive standard HFpEF medical care throughout the study.
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score from Baseline to Week 20
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a validated patient-reported outcome measure assessing heart failure-specific quality of life. The change in the overall summary score from baseline to week 20 will be compared between the FMT group and the placebo group. Higher scores indicate better health status.
Time frame: Baseline, Week 4, Week 20
Change in NYHA Functional Class from Baseline to Week 20
New York Heart Association (NYHA) functional classification is used to assess the severity of heart failure symptoms. Changes in NYHA class from baseline to week 20 will be compared between groups.
Time frame: Baseline, Week 4, Week 20
Change in 6-Minute Walk Test (6MWT) Distance from Baseline to Week 20
The 6-minute walk test is a measure of functional capacity in patients with heart failure. The distance walked in 6 minutes will be assessed at baseline, week 4, and week 20 to evaluate changes in exercise tolerance.
Time frame: Baseline, Week 4, Week 20
Change in Serum N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) Level from Baseline to Week 20
Serum NT-proBNP is a key biomarker for heart failure severity. Levels will be measured at baseline, week 4, and week 20 to assess changes in cardiac strain.
Time frame: Baseline, Week 4, Week 20
Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Total Score from Baseline to Week 20
The MLHFQ is a patient-reported questionnaire evaluating the impact of heart failure on quality of life. Higher scores indicate greater impairment. Changes from baseline to week 20 will be compared.
Time frame: Baseline, Week 4, Week 20
Change in Serum Inflammatory Biomarkers (NLRP3, IL-1β, TNF-α, IL-6, MCP-1, ICAM-1, VCAM-1) from Baseline to Week 20
Serum levels of the following inflammatory and endothelial activation markers (all units: pg/mL) will be measured to assess the effect of FMT on systemic inflammation in patients with HFpEF: NLRP3, IL-1β, TNF-α, IL-6, MCP-1, ICAM-1, and VCAM-1. Each biomarker will be analyzed separately for changes from baseline.
Time frame: Baseline, Week 4, Week 20
Change in Gut Microbiota Composition and Diversity from Baseline to Week 20
Fecal samples will be collected for 16S rRNA sequencing to analyze changes in gut microbiota composition, diversity, and taxonomic profiles following FMT intervention.
Time frame: Baseline, Week 20
Change in Serum Nitric Oxide (NO) Level from Baseline to Week 20
Serum nitric oxide (NO) concentration will be measured as an indicator of vascular endothelial function.
Time frame: Baseline, Week 4, Week 20
Change in Frailty Status Using the Fried Frailty Phenotype Criteria from Baseline to Week 20
Frailty status will be assessed using the Fried criteria to evaluate changes in physical vulnerability.
Time frame: Baseline, Week 20
Change in Nutritional Status Using the Mini Nutritional Assessment (MNA) Scale from Baseline to Week 20
Nutritional status will be evaluated using the Mini Nutritional Assessment (MNA) scale. Changes in total score from baseline to week 20 will be compared.
Time frame: Baseline, Week 20
Change in Basic Activities of Daily Living (BADL) Scale Score from Baseline to Week 20
The Basic Activities of Daily Living (BADL) scale will be used to assess changes in patients' functional independence in daily activities.
Time frame: Baseline, Week 20
Change in SARC-F Scale Score from Baseline to Week 20
The SARC-F questionnaire is a validated tool for sarcopenia screening, assessing strength, assistance with walking, rising from a chair, climbing stairs, and falls. Changes in total score from baseline to week 20 will be evaluated.
Time frame: Baseline, Week 20
Change in Fecal Short-Chain Fatty Acids (SCFAs) from Baseline to Week 20
Concentrations of fecal short-chain fatty acids (including acetate, propionate, and butyrate) will be quantified (unit: μmol/g) to assess changes in gut microbial fermentation.
Time frame: Baseline, Week 20
Change in Serum Trimethylamine N-Oxide (TMAO) from Baseline to Week 20
Serum TMAO level will be measured (unit: μM) as a marker of gut microbiota-dependent metabolism of dietary phosphatidylcholine and carnitine.
Time frame: Baseline, Week 20
Change in Serum Bile Acids Profile from Baseline to Week 20
Serum concentrations of primary and secondary bile acids (e.g., cholic acid, deoxycholic acid) will be quantified (unit: μM) to evaluate changes in bile acid metabolism.
Time frame: Baseline, Week 20
Change in Serum Indole-3-Propionate (IPA) from Baseline to Week 20
Serum IPA level will be measured (unit: μM) as a gut microbiota-derived tryptophan metabolite.
Time frame: Baseline, Week 20
Change in Serum Indoxyl Sulfate from Baseline to Week 20
Serum indoxyl sulfate level will be quantified (unit: μM) as a representative gut microbiota-derived uremic toxin.
Time frame: Baseline, Week 20
Change in White Blood Cell (WBC) Count from Baseline to Week 20
WBC count will be measured (unit: ×10⁹/L) to monitor changes in systemic inflammatory/immune status.
Time frame: Baseline, Week 4, Week 20
Change in Hemoglobin (HGB) Concentration from Baseline to Week 20
Hemoglobin concentration will be measured (unit: g/L) to assess changes in oxygen-carrying capacity.
Time frame: Baseline, Week 4, Week 20
Change in Platelet (PLT) Count from Baseline to Week 20
Platelet count will be measured (unit: ×10⁹/L) to evaluate changes in hemostatic/thrombotic potential.
Time frame: Baseline, Week 4, Week 20
Change in Serum Creatinine from Baseline to Week 20
Serum creatinine level will be measured (unit: μmol/L) to assess renal function.
Time frame: Baseline, Week 4, Week 20
Change in Estimated Glomerular Filtration Rate (eGFR) from Baseline to Week 20
eGFR will be calculated (unit: mL/min/1.73m²) as a marker of renal function.
Time frame: Baseline, Week 4, Week 20
Change in Alanine Aminotransferase (ALT) from Baseline to Week 20
Serum ALT level will be measured (unit: U/L) to assess hepatocellular integrity.
Time frame: Baseline, Week 4, Week 20
Change in Aspartate Aminotransferase (AST) from Baseline to Week 20
Serum AST level will be measured (unit: U/L) to assess hepatocellular integrity.
Time frame: Baseline, Week 4, Week 20
Change in Fasting Blood Glucose from Baseline to Week 20
Fasting blood glucose concentration will be measured (unit: mmol/L) to assess glycemic status.
Time frame: Baseline, Week 4, Week 20
Change in Serum Electrolytes (Sodium, Potassium, Chloride) from Baseline to Week 20
Serum concentrations of sodium (Na⁺), potassium (K⁺), and chloride (Cl-) will be measured (all units: mmol/L). Each electrolyte will be analyzed separately for changes from baseline.
Time frame: Baseline, Week 4, Week 20
Change in Left Atrial Volume Index (LAVI) from Baseline to Week 20
LAVI (unit: mL/m²) will be measured to assess changes in left atrial remodeling.
Time frame: Baseline, Week 4, Week 20
Change in Left Ventricular Mass Index (LVMI) from Baseline to Week 20
LVMI (unit: g/m²) will be measured to assess changes in left ventricular hypertrophy.
Time frame: Baseline, Week 4, Week 20
Change in Pulmonary Artery Systolic Pressure (PASP) from Baseline to Week 20
PASP (unit: mmHg) will be measured to assess changes in pulmonary artery pressure.
Time frame: Baseline, Week 4, Week 20
Change in E/e' Ratio from Baseline to Week 20
The E/e' ratio (unitless) will be measured to assess changes in left ventricular filling pressure.
Time frame: Baseline, Week 4, Week 20
Change in Serum Diamine Oxidase (DAO) from Baseline to Week 20
Serum DAO level (unit: U/L) will be measured to assess changes in intestinal barrier integrity.
Time frame: Baseline, Week 4, Week 20
Change in Serum D-Lactate from Baseline to Week 20
Serum D-lactate level (unit: μmol/L) will be measured to assess changes in intestinal permeability.
Time frame: Baseline, Week 4, Week 20
Change in Serum Endotoxin from Baseline to Week 20
Serum endotoxin level (unit: EU/mL) will be measured to assess changes in bacterial translocation and intestinal barrier function.
Time frame: Baseline, Week 4, Week 20
Change in Total Body Fat Mass from Baseline to Week 20
Body fat mass will be measured (unit: kg) to assess changes in adiposity.
Time frame: Baseline, Week 20
PDFs hosted by the registry, ClinicalTrials.gov.
Start is estimated for Jun 2026; primary completion for Mar 2027, 9 months later.
Of 43 phase 1/2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Air Force Medicial University